Core Insights - The 2025 Future Medical and Pharmaceutical Top 100 Exhibition (VBEF) was held in Suzhou, showcasing advancements in medical technology, with Shenzhen Beixin Life Technology Co., Ltd. recognized in the "Top 100 Chinese Innovative Medical Devices and Intelligent Manufacturing" list [1] - Beixin Life's core product, the Intravascular Ultrasound (IVUS) system, won the "Best Intelligent Medical Device Technology Innovation Product" award, marking a significant achievement in the cardiovascular precision intervention field [1][2] - The company has successfully broken the long-standing dominance of imported products in China's cardiovascular precision diagnosis market, completing this transition in nine years [1] Product and Technology Highlights - The IVUS system features a 60MHz imaging resolution, high retraction speed, and intelligent operation, establishing a strong position in the domestic market [2] - It is the first domestically developed IVUS system approved under the EU MDR, successfully entering international markets [2] - The FFR (Fractional Flow Reserve) system, another core product, is recognized as the first domestically approved gold standard FFR system, showcasing Beixin Life's technological leadership [2] Innovation and Development - Beixin Life has established four core technology platforms: micro-nano device research and packaging, interventional catheter research and processes, high-performance medical hardware development, and high-performance signal and image algorithms [2][3] - The company has launched 11 commercialized products based on these platforms, obtaining over 20 Class III medical device registration certificates, and serving more than 1,000 hospitals and 150,000 patients globally [2] - The IVUS system incorporates advanced features such as the inSmartVision platform for automatic image analysis and the EasyGO function for angiography registration, enhancing clinical efficiency and reducing procedure time [3] Future Aspirations - Beixin Life aims to continue its mission of improving life and health through innovation and quality, aspiring to become a world-class medical technology enterprise with lasting influence [3] - The recognition from the awards and the inclusion in the top 100 list serve as validation of the company's technological innovations and clinical value, motivating further advancements in the cardiovascular precision intervention sector [3]

Core Insights - The National Medical Products Administration of China emphasizes support for high-end medical device innovation, particularly in advanced medical imaging equipment, to address the growing global demand for cardiovascular disease treatment solutions [1] - Beixin Life, a domestic company focused on high-end medical device innovation, aims to develop high-performance interventional medical devices to tackle the significant public health issue of cardiovascular diseases [1][3] - The company has successfully developed and commercialized proprietary high-performance diagnostic equipment, contributing to the advancement of domestic high-end medical devices [1][3] Industry Overview - Coronary heart disease is recognized as a major health threat globally, with cardiovascular diseases being the leading cause of death in China [2] - China has the highest annual volume of percutaneous coronary intervention (PCI) procedures, with a trend towards precision treatment guided by advanced coronary functional and imaging technologies [2] - The reliance on imported devices and materials has historically dominated the market due to high R&D barriers and long return cycles [2] Company Achievements - Since its establishment in 2015, Beixin Life has developed a series of intelligent cardiovascular interventional solutions, including the first domestically approved IVUS and FFR systems [3][4] - The company has obtained over 20 Class III medical device registrations and successfully launched 11 products [3] - Beixin Life is the only domestic company with the technology to develop and manufacture 60MHz high-frequency micro-ultrasound transducers and MEMS pressure sensor modules [4] Market Potential - The cardiovascular device market is the second largest globally and is expected to grow rapidly over the next decade, with a significant patient population for coronary heart disease [7] - The number of PCI procedures in China is projected to increase from 1.906 million in 2024 to 4.298 million by 2030, with a compound annual growth rate of approximately 14.5% [7] - The precision PCI market in China is expected to grow from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, with a compound annual growth rate exceeding 20% [7] Competitive Position - Beixin Life's FFR product captured 30.6% of the domestic market share shortly after its launch, while its IVUS product became the leading domestic option, reducing reliance on imports [8] - The company has successfully expanded its products to international markets, receiving positive feedback and achieving routine clinical use in multiple countries [8] - Beixin Life aims to enhance the synergy of its product system and adapt to international markets, thereby improving the global competitiveness of China's high-performance medical device industry [9]

在国家高性能医疗器械创新中心发布的2024年度医疗器械行业创新生态洞察评估中，北芯生命凭借科技 创新实力和出海成果，成功入选"2024年医疗器械行业新锐企业100强创新指数"榜单以及"2024年医疗器 械行业海外拓展卓越企业"榜单。这不仅是对北芯生命过往努力的认可，也预示着其在未来行业发展中 具备巨大潜力。 未来，北芯生命将继续以"成为有长久影响力的世界级医疗科技企业"为愿景，持续投入研发，为全球心 血管疾病患者带来更多优质的诊疗选择，推动心血管精准介入领域不断向前发展。 深圳北芯生命科技股份有限公司(以下简称"北芯生命")自2015年成立以来，始终专注于心血管疾病精准 诊疗创新医疗器械的研发、生产与销售。秉持"用创新和品质改善生命健康"的使命，北芯生命在该领域 不断深耕，取得了一系列成果。 历经九年多的研发创新，北芯生命逐步打破海外巨头在心血管精准介入领域的垄断局面，填补多项国产 空白。其境内外已获批十余张三类医疗器械注册证。截至2025 年 6 月 30 日，公司拥有 185 项境内外授 权专利，其中发明专利 86 项。 北芯生命自主研发的血管内超声(IVUS)系统为中国首个获批的国产高清(60 MHz) ...

作为国产心血管精准介入器械领域的领军企业，北芯在核心产品线持续巩固市场优势。 作为一家成立九年多的中国本土的创新医疗（002173）器械企业，深圳北芯生命科技股份有限公司(简 称"北芯")通过不断成功研发和商业化具有自主知识产权的诊疗装备，致力于提高高端医疗设备市场国 产化率，为全球日益增长的心血管疾病诊疗需求带来变革的精准解决方案。 2024年营收同比增长超70%，显经营韧性 数据显示，北芯2024年营业收入高速增长，2022年、2023年、2024年度，北芯实现营业收入分别为 9245.19万元、18397.72元和31660.43万元，2024年营业收入同比增长超70%，呈高速增长态势。随着在 研产品持续商业化，预计北芯各产品线将继续带动收入增速及市占率的增长。 值得注意的是，北芯经营活动产生的现金流量为正，亏损大幅收窄并接近盈亏平衡。与此同时，2024 年，北芯销售费用率、管理费用率分别下降约21个百分点、约26个百分点，整体经营效率明显提升， 2025年将实现规模化利润。 国产领航者地位稳固，创新驱动行业高质量发展 2025年，公司新增新一代功能影像一体化解决方案，并推出首个国产全冠脉功能学一体化评 ...

Core Viewpoint - North Chip Life Technology Co., Ltd. is preparing for its IPO on the Sci-Tech Innovation Board, focusing on innovative medical devices in the cardiovascular precision intervention field [1] Company Overview - Established in 2015, North Chip Life specializes in high-performance active interventional devices for major diseases such as coronary heart disease and atrial fibrillation [1] - The company has developed key technologies, including the first domestically developed FFR system and a 60MHz high-speed IVUS system, breaking foreign monopolies [1] - Over ten products have been commercialized, with FFR and IVUS systems used in approximately 1,000 hospitals globally [1] Research and Development - North Chip Life has significantly increased R&D investment, establishing four technical platforms covering the entire chain from core sensor packaging to image analysis algorithms [1] - The company has applied for over 360 patents, with more than 180 granted, including over 80 invention patents and 14 PCT international patent applications [2] Financial Performance - Revenue figures for 2022, 2023, and 2024 are approximately 0.92 billion, 1.84 billion, and 3.17 billion respectively, with positive operating cash flow and narrowing losses [2] - Sales and management expense ratios are projected to decrease by about 21 percentage points and 26 percentage points respectively in 2024, indicating improved operational efficiency [2] Market Potential - The number of PCI procedures in China reached 1.636 million in 2023, expected to grow to 4.3 million by 2030, driving demand for the company's core products [3] - The precision PCI market in China is projected to grow from 2.04 billion in 2022 to 9.42 billion by 2030, with a compound annual growth rate exceeding 20% [3] Global Expansion - North Chip Life is the first domestic company to obtain EU CE/MDR certification for both FFR and IVUS products, with regular supply to countries like Germany, the UK, and Italy [2] - In 2024, overseas revenue reached approximately 38.83 million, a year-on-year increase of nearly 160% [2] Vision and Future Plans - The company aims to become a world-class medical technology enterprise with a long-lasting impact, focusing on technology accumulation, product matrix, and global layout [3] - With a solid R&D capability and high-performance product matrix, North Chip Life is positioned to become a representative enterprise in the high-end medical device sector in China [3]